Royal Bank of Canada Decreases Position in Avantor, Inc. $AVTR

Royal Bank of Canada trimmed its position in Avantor, Inc. (NYSE:AVTR) by 21.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 230,629 shares of the company’s stock after selling 63,355 shares during the period. Royal Bank of Canada’s holdings in Avantor were worth $1,808,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of AVTR. Empowered Funds LLC boosted its stake in shares of Avantor by 40.3% in the first quarter. Empowered Funds LLC now owns 17,659 shares of the company’s stock worth $286,000 after acquiring an additional 5,075 shares during the last quarter. Cetera Investment Advisers raised its stake in Avantor by 40.2% in the 2nd quarter. Cetera Investment Advisers now owns 40,289 shares of the company’s stock valued at $542,000 after purchasing an additional 11,543 shares during the last quarter. Quantbot Technologies LP acquired a new position in Avantor in the 2nd quarter valued at $232,000. Arrowstreet Capital Limited Partnership lifted its holdings in Avantor by 214.9% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 124,076 shares of the company’s stock valued at $1,670,000 after purchasing an additional 84,679 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in Avantor by 119.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,187 shares of the company’s stock worth $29,000 after purchasing an additional 1,189 shares during the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Avantor Stock Down 1.0%

NYSE AVTR opened at $13.36 on Wednesday. Avantor, Inc. has a 52 week low of $7.26 and a 52 week high of $15.93. The company has a quick ratio of 1.18, a current ratio of 1.78 and a debt-to-equity ratio of 0.65. The business’s fifty day simple moving average is $11.35 and its 200-day simple moving average is $9.57. The firm has a market cap of $9.04 billion, a PE ratio of -15.91, a P/E/G ratio of 10.29 and a beta of 0.89.

Avantor (NYSE:AVTR) last announced its quarterly earnings data on Wednesday, July 29th. The company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.02. Avantor had a negative net margin of 8.81% and a positive return on equity of 9.92%. The firm had revenue of $1.69 billion during the quarter, compared to analyst estimates of $1.61 billion. During the same quarter in the prior year, the firm posted $0.24 earnings per share. Avantor’s quarterly revenue was up .5% on a year-over-year basis. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. As a group, equities analysts anticipate that Avantor, Inc. will post 0.81 earnings per share for the current year.

Analyst Upgrades and Downgrades

AVTR has been the subject of a number of research reports. Zacks Research raised shares of Avantor from a “strong sell” rating to a “hold” rating in a report on Thursday, April 30th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $13.00 price target on shares of Avantor in a research report on Thursday, July 30th. Jefferies Financial Group raised shares of Avantor from an “underperform” rating to a “hold” rating and set a $13.00 price objective for the company in a research note on Wednesday, July 29th. Evercore set a $10.50 price objective on shares of Avantor in a report on Monday, July 6th. Finally, Citigroup raised their target price on shares of Avantor from $9.00 to $11.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. Two investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Avantor has an average rating of “Hold” and an average price target of $12.00.

About Avantor

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.